Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAIL for Ragweed Allergic Rhinoconjunctivitis
NCT01353079Phase 3Completed
- Sponsor
- Greer Laboratories, Inc.
- Start
- Apr 2011
- Primary completion
- Nov 2011
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 3 trial of ambrosia artemisiifolia allergen extract in allergic rhinoconjunctivitis (ARC), sponsored by Greer Laboratories, Inc.. Started Apr 2011; status: completed.
02
Drugs
ambrosia artemisiifolia allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01353079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01353079.